細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(化學(xué)發(fā)光免疫分析法)
CLIA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
- 編號USCA788Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長2h, 40min
- 檢測范圍27.4-20,000pg/mL
- 靈敏度最小可檢測劑量小于等于11.5pg/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 1764 ¥ 2520 ¥ 11340 ¥ 21420 ¥ 176400
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實驗結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測細(xì)胞程序性死亡蛋白1配體1(PDL1)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的細(xì)胞程序性死亡蛋白1配體1(PDL1)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 84-98 | 90 |
| EDTA plasma(n=5) | 80-101 | 86 |
| heparin plasma(n=5) | 90-105 | 94 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的細(xì)胞程序性死亡蛋白1配體1(PDL1)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中細(xì)胞程序性死亡蛋白1配體1(PDL1)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-105% | 97-105% | 94-103% | 97-104% |
| EDTA plasma(n=5) | 89-96% | 80-89% | 98-105% | 92-99% |
| heparin plasma(n=5) | 93-101% | 89-96% | 88-102% | 80-93% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100μL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。
實驗原理
將細(xì)胞程序性死亡蛋白1配體1(PDL1)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的細(xì)胞程序性死亡蛋白1配體1(PDL1)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的細(xì)胞程序性死亡蛋白1配體1(PDL1)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入底物。加入底物后會產(chǎn)生輝光型光信號。發(fā)射光強度和樣品中的細(xì)胞程序性死亡蛋白1配體1(PDL1)呈正相關(guān)。用化學(xué)發(fā)光儀測定相對光單位（RLU），計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA788Hu02 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA788Hu01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA788Hu61 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)活性蛋白 | Cell?culture;?Activity?Assays. |
| UEPA788Hu61 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA788Hu01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 | WB; ICC/IF |
| UFAA788Hu01 | 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 | Flow cytometry. |
| UFAA788Hu41 | 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(藻紅素標(biāo)記) | FCM |
| UFAA788Hu51 | 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(別藻藍(lán)蛋白標(biāo)記) | Flow cytometry. |
| UFAA788Hu81 | 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(異硫氰酸熒光素標(biāo)記) | Flow cytometry. |
| UMAA788Hu28 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | ICC/IF |
| UMAA788Hu22 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB. |
| URAA788Hu22 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組抗體 | ICC/IF; FCM |
| UMAA788Hu21 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; ICC/IF |
| UMAA788Hu23 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; ICC/IF |
| UMAA788Hu24 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA788Hu25 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | ICC/IF |
| UMAA788Hu27 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA788Hu29 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | ICC/IF |
| UMAA788Hu26 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB |
| URAA788Hu21 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)重組抗體 | WB; ICC/IF; FCM |
| ULAA788Hu72 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(生物素標(biāo)記) | WB |
| UFAA788Hu82 | 抗細(xì)胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(異硫氰酸熒光素標(biāo)記) | Flow cytometry. |
| UWEA788Hu | 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(酶聯(lián)免疫吸附試驗法,寬范圍) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USEA788Hu | 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA788Hu | 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA788Hu | 細(xì)胞程序性死亡蛋白1配體1(PDL1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UPSA788Hu01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)抗體對 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| UKSA788Hu01 | 細(xì)胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742] |
| Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592] |
| Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853] |
| Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046] |
| Eur J Cancer.? | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170] |
| Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007] |
| Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703] |
| Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990] |
| Oncotarget | Soluble?programmed?death-ligand?1?(sPDL1) and?neutrophil-to-lymphocyte?ratio?(NLR)?predictssurvival?in?advanced?biliary?tract?cancer?patients?treated?with palliative chemotherapy. [pubmed:27780932] |
| Oncotarget | High?post-treatment?serum?levels?of?soluble?programmed?cell?death?ligand?1?predict?earlyrelapse?and?poor?prognosis?in?extranodal?NK/T?cell?lymphoma patients. [pubmed:27105512] |
| Oncotarget.? | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569] |
| Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165] |
| Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525] |
| Allergology International? | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514] |
| American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164] |
| Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759] |
| Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471] |
| Translational?Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935] |
| Immunology?Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481] |
| Journal of?Cancer?Research?and?Clinical?Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213] |
| Annals?of?Surgical?Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between?… [Pubmed: 30565045] |
| American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744] |
| PLoS?One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?… [Pubmed: 30807610] |
| Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406] |
| Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979] |
| Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543] |
| PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
| Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467] | |
| LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918] |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816] |
| Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313] | |
| Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997] |
| Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502] |
| EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707] |
| Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492] |
| Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426] |
| Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974] |
| Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A?… [Pubmed:35208526] |
留言咨詢
